Impairment of debrisoquine 4-hydroxylase and related monooxygenase activities in the rat following treatment with propranolol
Authors:
- Shoichi FujitaSFShoichi Fujita
- Masato ChibaMCMasato Chiba
- Noriko KagimotoNKNoriko Kagimoto
- Shin UmedaSUShin Umeda
- Tokuji SuzukiTSTokuji Suzuki
- 1 March 1991
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 41 (6-7) , 861-865
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Quinidine reduces clearance of (+)-propranolol more than (−)-propranolol through marked reduction in 4-hydroxylationClinical Pharmacology & Therapeutics, 1990
- Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activitiesClinical Pharmacology & Therapeutics, 1989
- Irreversible binding and metabolism of propranolol by human liver microsomes—Relationship to polymorphic oxidationBiochemical Pharmacology, 1987
- Debrisoquine 4-Hydroxylase: Characterization of a New P450 Gene Subfamily, Regulation, Chromosomal Mapping, and Molecular Analysis of the DA Rat PolymorphismDNA, 1987
- Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockadeClinical Pharmacology & Therapeutics, 1984
- The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.British Journal of Clinical Pharmacology, 1984
- Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in manEuropean Journal of Clinical Pharmacology, 1984
- Defective Oxidation of DrugsClinical Pharmacokinetics, 1982
- Polymorphisms of Oxidation at Carbon Centers of Drugs and Their Clinical SignificanceDrug Metabolism Reviews, 1979
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977